Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Part of paid clinical trials in Orange, California.

Sponsor
University of California, Irvine
Study ID
NCT07693452
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Appendiceal Mucinous Neoplasm
  • Pseudomyxoma Peritonei

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Metformin — DRUG
    Given PO

Study Details

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Key Dates

First listed
Jul 9, 2026
Start date
Jun 18, 2026
Status verified
Jul 2026
Primary completion
Feb 29, 2028
Completion
Jul 31, 2029

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Metformin Treatment
    850mg PO daily

Primary Outcome Measure

Proportion of Participants who have completed at least (≥) 80% of planned metformin doses by 6 months [ Time Frame: 6 months ]

Central Contacts

  • Chao Family Comprehensive Cancer Center University of California, Irvine
    1-877-827-8839
    [email protected]
  • University of California Irvine Medical

Locations (1)

FacilityCityStateZIPSite coordinators
Chao Family Comprehensive Cancer Center, University of California, IrvineOrangeCalifornia92868
Oliver Eng, MD
[email protected]
877-827-8839

Find similar trials in Orange, CA

By research site
Chao Family Comprehensive Cancer Center, University of California, Irvine· Orange, CA

Related Studies